AYTUAYTU BIOPHARMA, INC
- Earnings Call Transcripts
AYTU BIOPHARMA (NASDAQ: AYTU) COMPANY PRESENTATION | LYTHAM PARTNERS FALL 2026 INVESTOR CONFERENCE - AYTU BIOPHARMA INC
All right. Hello, everyone, and thank you all for joining us during the Litham Partners Fall 2026 Investor Conference. Again, my name is Robert Bloom, Managing Partner here at Litham Partners. And up next, Josh Disbrough ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma with a Buy and raises the price target from $14.5 to $15. ...
- Earnings Call Transcripts
Aytu BioPharma Fiscal 2026 Full Year and Q4 Earnings Call - AYTU BIOPHARMA INC
Greetings. Welcome to the A2 Biopharma Fiscal 2026 Full Year and Q4 Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone sh ...
- AccessWire
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6 million in fiscal ...
- AccessWire
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma with a Buy and raises the price target from $14 to $14.5. ...
- AccessWire
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases ...
- AccessWire
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases ...
- AccessWire
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth ratesTotal net revenue of $12.4 millionAdjusted EBITDA1 of ...
- AccessWire
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to ...
- US FDA
Approval of Karbinal Er, Nda #022556 (Labeling)
Approval Date: 03/10/2026; Drug Name: Karbinal Er, Nda #022556; Active Ingredients: CARBINOXAMINE MALEATE; Company: Aytu; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022556 ...
- Earnings Call Transcripts
Aytu BioPharma Fiscal 2026 Q2 Earnings Call - AYTU BIOPHARMA INC
Good day, everyone, and welcome to the A2 Biopharma Fiscal 2026 Second Quarter Earnings Call. At this time, all participants are placed on a listen-only mode, and we will open the floor for your questions and comments af ...
- AccessWire
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Total net revenue of $15.2 millionAdjusted EBITDA1 of $ million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ extended-release ...
- AccessWire
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system ...
- AccessWire
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient ...
- AccessWire
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system ...
- AccessWire
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system ...
- AccessWire
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma with a Buy and raises the price target from $12.5 to $13. ...
- AccessWire
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central ...
- AccessWire
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Total net revenue of $13.9 millionNet income of $2.0 million, or $0.21 net income per share basicAdjusted EBITDA1 of $ million, which includes EXXUA launch investments$32.6 million cash balance at September 30, ...
- AccessWire
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central ...
- AccessWire
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central ...
- AccessWire
Aytu BioPharma to Present at Upcoming October 2025 Conferences
DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. , a pharmaceutical company focused on ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - AYTU BIOPHARMA, INC (0001385818) (Issuer)
Statement of changes in beneficial ownership of securities ...